- BrainStorm Cell Therapeutics (NASDAQ:BCLI) announces the promotion of Bob Dagher to Executive Vice President and Chief Medical Officer.
- The company said it is undergoing strategic management changes as it prepares for the Phase 3b trial of NurOwn®, its investigational cell therapy treatment for amyotrophic lateral sclerosis (ALS).
- In addition, after four years of maintaining top executive roles, Stacy Lindborg is stepping down from the role of co-CEO and will transition to the board of directors.
- Dagher's responsibilities will include overseeing the planned Phase 3b registration trial of NurOwn.
Dagher has over 20 years of experience in clinical research and development and has served at BrainStorm since July 2023 as Chief Development Officer.
More on BrainStorm Cell Therapeutics
- BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy
- BrainStorm submits SPA request to FDA for Phase 3 study design
- Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics
- Historical earnings data for BrainStorm Cell Therapeutics
- Financial information for BrainStorm Cell Therapeutics